- Home
- Publications
- Publication Search
- Publication Details
Title
Isavuconazole for COVID-19-Associated Invasive Mold Infections
Authors
Keywords
-
Journal
Journal of Fungi
Volume 8, Issue 7, Pages 674
Publisher
MDPI AG
Online
2022-06-28
DOI
10.3390/jof8070674
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID‐19‐associated aspergillosis in a Brazilian referral centre: Diagnosis, risk factors and outcomes
- (2022) João N. de Almeida et al. MYCOSES
- The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries
- (2022) Martin Hoenigl et al. Lancet Microbe
- Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support
- (2022) Michelle Miller et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy
- (2021) Christoph Zurl et al. Journal of Fungi
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
- (2021) Rita Humeniuk et al. CLINICAL PHARMACOKINETICS
- Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study
- (2021) Tobias Lahmer et al. PLoS One
- Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole
- (2021) Malene Risum et al. Antibiotics-Basel
- Penetration of Isavuconazole in Ascites Fluid of Critically Ill Patients
- (2021) Tobias Lahmer et al. Journal of Fungi
- Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021
- (2021) Jochem B Buil et al. Eurosurveillance
- Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review
- (2021) Daniel Echeverria-Esnal et al. Expert Review of Anti-Infective Therapy
- Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis
- (2021) Paul E. Verweij et al. INTENSIVE CARE MEDICINE
- Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry
- (2021) Juergen Prattes et al. INTENSIVE CARE MEDICINE
- Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019)
- (2021) Michael A. Pfaller et al. JOURNAL OF ANTIBIOTICS
- Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience
- (2021) Ilona Kronig et al. MYCOPATHOLOGIA
- COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States
- (2021) Anastasia I. Wasylyshyn et al. MYCOPATHOLOGIA
- Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World
- (2021) Valliappan Muthu et al. MYCOPATHOLOGIA
- ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries
- (2021) Shivaprakash M. Rudramurthy et al. MYCOSES
- COVID-19-associated rhino-orbital mucormycosis: a single-centre experience of 10 cases
- (2021) R Arjun et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion
- (2021) Frank L van de Veerdonk et al. Lancet Respiratory Medicine
- Fungal Taxa Responsible for Mucormycosis/“Black Fungus” among COVID-19 Patients in India
- (2021) Pradeep K. Divakar Journal of Fungi
- Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital
- (2021) Elisabeth Paramythiotou et al. Infectious Diseases and Therapy
- Five probable factors responsible for the COVID-associated mucormycosis outbreak in India
- (2021) Khaiwal Ravindra et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Results from a national survey on COVID‐19‐associated mucormycosis in Germany: 13 patients from six tertiary hospitals
- (2021) Danila Seidel et al. MYCOSES
- Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study
- (2021) Jean-Pierre Gangneux et al. Lancet Respiratory Medicine
- Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
- (2021) Pier Giorgio Cojutti et al. Pharmaceutics
- Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly Complication
- (2021) François Danion et al. Open Forum Infectious Diseases
- Coronavirus Disease 2019–Associated Invasive Fungal Infection
- (2021) John W Baddley et al. Open Forum Infectious Diseases
- A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA)
- (2021) Simon Feys et al. Journal of Fungi
- A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT)
- (2020) Anat Stern et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study
- (2020) Prithviraj Bose et al. CLINICAL INFECTIOUS DISEASES
- Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients
- (2020) Palash Samanta et al. CLINICAL INFECTIOUS DISEASES
- COVID‐19 associated pulmonary aspergillosis
- (2020) Philipp Koehler et al. MYCOSES
- Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge
- (2020) Spinello Antinori et al. Travel Medicine and Infectious Disease
- COVID-19-associated invasive pulmonary aspergillosis
- (2020) Lynn Rutsaert et al. Annals of Intensive Care
- Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19
- (2020) C. Poignon et al. CLINICAL MICROBIOLOGY AND INFECTION
- Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube
- (2020) Erin K McCreary et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center
- (2020) Andrew M Borman et al. MEDICAL MYCOLOGY
- Isolation of Aspergillus spp. in respiratory samples of patients with COVID‐19 in a Spanish tertiary care hospital
- (2020) I Falces‐Romero et al. MYCOSES
- Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience
- (2020) Jean-Pierre Gangneux et al. Journal of Fungi
- Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations
- (2020) Christoph Zurl et al. Journal of Fungi
- Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis
- (2020) Chris Kosmidis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single‐center experience
- (2020) Christine A. Vu et al. Transplant Infectious Disease
- COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?
- (2020) Amir Arastehfar et al. Journal of Fungi
- Occurrence of Invasive Pulmonary Fungal Infections in Severe COVID-19 Patients Admitted to the ICU
- (2020) Arnaud Fekkar et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance
- (2020) Dinesh Singh Moirangthem et al. CURRENT DRUG TARGETS
- Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity
- (2020) Marina Machado et al. MYCOSES
- Isavuconazole brain penetration in cerebral aspergillosis
- (2019) F Lamoth et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients
- (2019) Lauren Fontana et al. CLINICAL INFECTIOUS DISEASES
- Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy
- (2019) E Furfaro et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre
- (2019) Christina D. Bowen et al. MYCOSES
- Molecular identification, antifungal susceptibility testing and mechanisms of azole resistance in Aspergillus spp. received within a surveillance program on antifungal resistance in Spain
- (2019) Olga Rivero-Menendez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children
- (2019) A. Warris et al. CLINICAL MICROBIOLOGY AND INFECTION
- Isavuconazole Diffusion in Infected Human Brain
- (2019) Claire Rouzaud et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
- (2019) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation
- (2019) Yanjun Zhao et al. PHARMACOTHERAPY
- Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials
- (2018) David Andes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole
- (2018) Caitlin R Rausch et al. CLINICAL INFECTIOUS DISEASES
- Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
- (2018) Monica Fung et al. CLINICAL INFECTIOUS DISEASES
- Validation of an Isavuconazole High-Performance Liquid Chromatography Assay in Plasma for Routine Therapeutic Drug Monitoring Applications
- (2018) Silke C. Mueller et al. THERAPEUTIC DRUG MONITORING
- Molecular Detection of Azole-Resistant Aspergillus fumigatus in Clinical Samples
- (2018) Jochem B. Buil et al. Frontiers in Microbiology
- Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study
- (2018) Alexander F A D Schauwvlieghe et al. Lancet Respiratory Medicine
- Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients
- (2018) Xuemei Wu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study
- (2018) Pieter P Lestrade et al. CLINICAL INFECTIOUS DISEASES
- Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
- (2018) Thomas Kaindl et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs
- (2017) Jochem B Buil et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
- (2016) Laura L. Kovanda et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
- (2016) Amit Desai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
- (2016) Amit Desai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH
- (2016) Anne Schmitt-Hoffmann et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
- (2016) Johan A Maertens et al. LANCET
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
- (2016) Francisco M Marty et al. LANCET INFECTIOUS DISEASES
- Potential drug–drug interactions in hospitalised haematological patients
- (2016) Ma Ángeles Fernández de Palencia Espinosa et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study
- (2015) Oliver A. Cornely et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Isavuconazole and Comparators against Clinical Isolates of theMucoralesOrder
- (2015) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntifungal Activity of Isavuconazole against Madurella mycetomatis
- (2012) Wendy Kloezen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557
- (2009) A. Schmitt-Hoffmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started